Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P6 vs Herceptin plus paclitaxel in metastatic breast cancer
2009-016197-33Phase 3Completed
- Sponsor
- Celltrion
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab in breast cancer (2 arms), sponsored by Celltrion. Primary endpoint: Overall response rate at 6 months. Started Feb 2010; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-016197-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016197-33.